Paper Details

  1. Home
  2. Paper Details

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.

Author: CorboMichael, DelaetIngrid, ElegbeAyanbola, GenoveseMark C, KivitzAlan J, LudivicoCharles, NashPeter, NayiagerSauithree, OelkeKurt, PalmerWilliam, RodriguezCristian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Subcutaneous abatacept did not elicit immunogenicity associated with loss of safety or efficacy, either with or without methotrexate.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the impact of concomitant methotrexate (MTX) on subcutaneous (SC) abatacept immunogenicity, and to assess safety and efficacy. METHODS: This phase III, open-label study had a 4-month short-term (ST) period and an ongoing long-term extension (LTE) period. Rheumatoid arthritis ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/acr.21876

データ提供：米国国立医学図書館（NLM）

Abatacept for Rheumatoid Arthritis: Exploring Subcutaneous Delivery and Immunogenicity

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation and joint damage. Finding effective and safe treatments for RA is a priority in rheumatology research. This phase III clinical trial investigates the safety and efficacy of subcutaneous (SC) abatacept, a biologic medication that targets T-cell activation, in patients with RA. The researchers compared the immunogenicity (development of antibodies against abatacept) and efficacy of SC abatacept administered with or without methotrexate (MTX). Their findings suggest that SC abatacept is a safe and effective treatment for RA, regardless of whether it is administered with or without MTX, and that immunogenicity is minimal.

Subcutaneous Abatacept: A Convenient and Effective Treatment Option for Rheumatoid Arthritis

The study found that SC abatacept effectively reduced disease activity and improved symptoms in patients with RA. Furthermore, the low incidence of immunogenicity suggests that SC abatacept is well-tolerated and maintains its efficacy over time. This suggests that SC abatacept could become a valuable treatment option for patients with RA, offering a convenient and effective alternative to intravenous administration.

Optimizing RA Treatment Strategies

The findings of this study provide further support for the use of abatacept in the management of RA. The researchers found that SC abatacept is a safe and effective treatment, offering a convenient and well-tolerated option for patients. This reinforces the importance of individualized treatment approaches, carefully considering the specific needs of each patient and the potential benefits and risks of different therapies.

Dr. Camel's Conclusion

This research is like a camel discovering a new oasis in the desert, offering a convenient and effective way to quench the thirst of RA patients. Subcutaneous abatacept provides a promising and well-tolerated treatment option, potentially improving the lives of many individuals struggling with this debilitating disease. As with any journey, careful monitoring and adjustments may be necessary to ensure the optimal path to recovery.

Date :
  1. Date Completed 2013-06-17
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

23097311

DOI: Digital Object Identifier

10.1002/acr.21876

Related Literature

Article Analysis
・Effects of abatacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.